We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Eirx Therap. | LSE:ERX | London | Ordinary Share | GB00B0XQBS97 | ORD 0.001P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.015 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:8349O EiRx Therapeutics PLC 27 February 2008 EIRX THERAPEUTICS PLC ( "EiRx" or "the Company" ) Receipt of Grant Payment Cork, Ireland - EiRx Therapeutics plc (AIM: ERX), the drug discovery company developing targeted therapies for cancer, is pleased to announce it has received a final payment of Euro219,157.40 from the European Commission under the Company's Marie Curie Host Fellowships for the Transfer of Knowledge grant. This grant was awarded to EiRx by the Commission as part of its Sixth Framework Programme for Research and Technological Development, as previously announced on 4 March 2005. Payment draw-down under the grant, which was awarded to the Company to support its move from drug target discovery to the higher value discovery and development of candidate cancer drugs, was linked to expenditure incurred by the Company in the course of the research programme. The current payment brings the total sum drawn down by the Company to Euro524,216.45, from a total approved maximum of Euro575,414.00. EiRx was one of the first companies to be awarded a grant under the Marie Curie TOK scheme, which supports European Companies demonstrating technical, managerial and scientific excellence. Commenting on the payment, EiRx Chairman John Pool said: "The Directors would like to express their appreciation to the Commission for the support received under the Marie Curie programme, which has supported the establishment of the Company's Engineered Pathway Dependence (EnPADTM) technology platform for the rapid, low-cost discovery of targeted cancer drug candidates. We look forward to progressing certain of these candidate compounds through our medicinal chemistry collaboration with the Analytical and Biological Chemistry Research Facility at University College Cork, which is being supported with further grant funding from Enterprise Ireland's Innovation Partnership scheme." For further information, please contact: EiRx Therapeutics plc +353 (0)21 432 0847 Colin Telfer PhD, Chief Executive Officer Grant Thornton Corporate Finance +44 (0)20 7383 5100 Philip Secrett / Colin Aaronson About EiRx EiRx Therapeutics (AIM: ERX) is a research-driven healthcare company developing cutting-edge targeted therapies for the treatment of cancer. Headquartered in Cork, Ireland, the Company conducts drug discovery focused on tumours arising due to anomalies in apoptosis and cellular growth regulatory pathways, with particular relation to breast and colorectal tumours, currently two of the four leading causes of death from cancer world-wide. EiRx is built on leading scientific expertise in the areas of apoptosis biology, cancer pathway biology, biomarker technologies and the metabolic basis of drug resistance in tumours. It has established technical capabilities in target identification, validation and cell-based screening, and is combining unique resources such as the ACCRI-BANK clinical tissue bank, the ALIBITM functional genomics platform and the Engineered Pathway Dependence ("EnPADTM") isogenic cellular screening technology to create a product development engine specialising in discovery and development of small-molecule targeted cancer therapies and the discovery and validation of cancer biomarkers. For further information please see our website at http://www.eirx.com Disclaimer The content of this notice reflects only the author's views and the European Commission does not accept any liability for any use that may be made of the information contained herein. ENDS This information is provided by RNS The company news service from the London Stock Exchange END MSCIIFFAFLIDFIT
1 Year Eirx Therapeutics Chart |
1 Month Eirx Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions